TRAF2 is a Valuable Prognostic Biomarker in Patients with Prostate Cancer.

Area of Science:

• Oncology
• Molecular Biology

Background:

• Tumor necrosis factor receptor-associated factor 2 (TRAF2) plays a role in cancer development and progression.
• Prostate cancer remains a significant health concern, necessitating improved prognostic markers.

Purpose of the Study:

• To evaluate TRAF2 as a prognostic biomarker in prostate cancer.
• To investigate TRAF2's role in regulating TRAIL-induced apoptosis in prostate cancer cells.

Main Methods:

• Utilized TCGA and GEO databases for gene expression analysis of TRAF2.
• Performed immunohistochemistry to assess TRAF2 protein levels in prostate cancer tissues.
• Employed Kaplan-Meier curves, log-rank tests, and Cox regression for survival analysis.
• Investigated TRAF2's effect on TRAIL-induced apoptosis in DU-145 cells.

Main Results:

• TRAF2 expression was significantly upregulated in prostate cancer compared to normal tissues and further elevated in metastatic disease.
• High TRAF2 expression correlated with advanced tumor stage and poorer recurrence-free survival.
• TRAF2 emerged as an independent prognostic factor for predicting recurrence-free survival.
• TRAF2 modulated TRAIL-induced apoptosis by regulating cleaved Caspase-8 and c-Flip expression.

Conclusions:

• TRAF2 is a promising novel prognostic biomarker for predicting recurrence-free survival in prostate cancer patients.
• TRAF2's association with prognosis may involve its regulation of TRAIL-induced apoptosis via the c-Flip/Caspase-8 signaling pathway.